News
Algea Therapies Launches SHIELD VCF System
May 23, 2013 5:12 pm | by The Associated Press | CommentsAUDUBON, Pa.--(BUSINESS WIRE)--May 23, 2013--Algea Therapies, a division of Globus Medical Inc. (NYSE: GMED), committed to finding innovative, minimally invasive solutions that treat pain and restore quality of life, today announced the launch of the SHIELD™ Vertebral Compression Fracture (VCF)...
Men Who Want to Stay Active, Feel Younger, and Remain Socially and Professionally Engaged Should Address Hearing Loss, BHI Advises
May 23, 2013 4:18 pm | by PR Newswire | CommentsWASHINGTON, May 23, 2013 /PRNewswire/ -- Hearing health affects a man's lifestyle, and if he wants to stay active, feel younger, and remain socially and professionally engaged, he should address any hearing loss he may be experiencing. This is the overriding message that the...
Hansen Medical to Exhibit Magellan Robotic System at 2013 Vascular Annual Meeting of the Society for Vascular Surgery
May 23, 2013 4:03 pm | by The Associated Press | CommentsHansen Medical, Inc. (NASDAQ: HNSN), a global leader in intravascular robotics, today announced that it will exhibit its Magellan Robotic System at the 2013 Vascular Annual Meeting® of the Society for Vascular Surgery from May 30 - June 1 at the Moscone West Convention Center in San...
First Large-Scale Population-Based Study in the U.S. Shows Hologic's 3D Mammography (Breast Tomosynthesis) Significantly Reduces Recall Rates While Simultaneously Improving Cancer Detection
May 23, 2013 10:28 am | by PR Newswire | CommentsHologic, Inc. has announced that the first large-scale observational study in a U.S. clinical practice comparing breast cancer screening with Hologic's 3D mammography technology with conventional 2D mammography alone showed a significant reduction in recall rates and a sizeable increase in cancer detection, particularly invasive cancer, across all breast tissue densities.
TOPS Comprehensive Breast Center Study Validates the Benefits of New 3D Mammography Technology in Breast Cancer Screening
May 23, 2013 10:24 am | by The Associated Press | CommentsHOUSTON--(BUSINESS WIRE)--May 23, 2013--The first large-scale U.S. study comparing conventional 2D mammography screening exams alone versus 2D mammography with the addition of 3D mammography (breast tomosynthesis) technology has been completed at TOPS Comprehensive Breast Center. The study showed...
Frequent Heartburn May Predict Cancers of the Throat and Vocal Cord
May 23, 2013 10:00 am | by AACR | CommentsFrequent heartburn was positively associated with cancers of the throat and vocal cord among nonsmokers and nondrinkers, and the use of antacids, but not prescription medications, had a protective effect, according to data published in Cancer Epidemiology, Biomarkers & Prevention, a journal of the American Association for Cancer Research.
Cardiovascular Systems Presents New Late-Breaking Coronary Results at EuroPCR Conference
May 23, 2013 10:00 am | by The Associated Press | CommentsST. PAUL, Minn.--(BUSINESS WIRE)--May 23, 2013--Cardiovascular Systems, Inc. (CSI) (NASDAQ: CSII), presented 30-day results from its ORBIT II study of coronary artery disease in a late-breaking presentation at the 2013 European Association of Percutaneous Cardiovascular Interventions (EuroPCR)...
Direct to Implant ("One Step") Mastectomy Breast Reconstruction Reduces Number of Surgeries and Time to Final Cosmetic Results
May 23, 2013 9:29 am | by PR Newswire | CommentsTARRYTOWN, N.Y., May 23, 2013 /PRNewswire/ -- Direct to implant, or "one step," breast reconstruction following mastectomy is an appropriate option for many women with BRCA (BReast CAncer) gene mutations seeking to surgically reduce their breast cancer risk, or with breast...
Study Finds 35 to 42 Percent Daily Cost Savings for Hospitals Using Flexi-Seal® Fecal Management System
May 23, 2013 9:00 am | by PR Newswire | CommentsSKILLMAN, N.J., May 23, 2013 /PRNewswire/ -- A new study of the costs of managing fecal incontinence in intensive care units (ICUs) at two Canadian hospitals has found a 35 to 42 percent decrease in daily material costs with the Flexi-Seal® Fecal Management System (FMS) compared...
Atossa Genetics to Exhibit Its ForeCYTE Breast Health Test at the 2013 ASCO Annual Meeting
May 23, 2013 8:30 am | by The Associated Press | CommentsAtossa Genetics, Inc. (NASDAQ: ATOS), The Breast Health Company, will display its ForeCYTE Breast Health Test at the 2013 American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago, from May 31 through June 4, 2013. Atossa's exhibit will be located in booth 2019...
Israel Brain Technologies Announces Israel's 1st International Brain Technology Conference
May 23, 2013 8:30 am | by PR Newswire | CommentsTEL AVIV, Israel, May 23, 2013 /PRNewswire/ -- Israel Brain Technologies (IBT) has announced the launch of BrainTech Israel 2013, Israel's 1st International Brain Technology Conference, which will take place on October 14th-15th in Tel Aviv, recently ranked as the 2nd most innovative...
Medtronic Completes Enrollment in Landmark U.S. Study of Symplicity Renal Denervation System for Treatment-Resistant Hypertension
May 23, 2013 6:06 am | by The Associated Press | CommentsMedtronic, Inc., today announced it has finished randomizing Symplicity HTN-3, the company's pivotal U.S. clinical trial of the Symplicity renal denervation system for treatment-resistant hypertension. Renal denervation is a minimally invasive, catheter-based procedure to reduce activity of the renal (kidney) nerves, which are part of the sympathetic nervous system and help regulate blood pressure.
InspireMD's MGuard Embolic Protection Stent (EPS) Shows Lower Mortality Rate in STEMI Patients at Six Months Compared to Control Group
May 23, 2013 6:00 am | by PR Newswire | CommentsInspireMD, Inc., the leader in embolic protection stents, today announced new 6-month results from the MASTER (MGuard for Acute ST Elevation Reperfusion) trial demonstrating that the MGuard Embolic Protection Stent (EPS) outperformed bare metal and drug eluting stents in all-cause mortality in ST segment elevation myocardial infarction (STEMI) patients.
Volcano Announces Preliminary Results from the ADVISE II Study and Inclusion in the SYNTAX2 Trial During Hot Line Late Breaking Clinical Trial Sessions at EuroPCR 2013
May 23, 2013 4:30 am | by PR Newswire | CommentsSAN DIEGO and PARIS, May 23, 2013 /PRNewswire/ -- Volcano Corporation (NASDAQ: VOLC), a leading developer and manufacturer of precision guided therapy tools designed to enhance the diagnosis and treatment of coronary and peripheral vascular disease, today announced preliminary...
One Year Data from St. Jude Medical Study Demonstrates Safe, Rapid and Sustained Blood Pressure Reduction with EnligHTN Renal Denervation Technology
May 23, 2013 4:15 am | by The Associated Press | CommentsST. PAUL, Minn. & PARIS--(BUSINESS WIRE)--May 23, 2013--St. Jude Medical, Inc. (NYSE:STJ), a global medical device company, today announced that the company’s EnligHTN ™ Multi-Electrode Renal Denervation System provides a safe, rapid and sustained reduction in blood pressure measurements after...
